Join us for the UNITY Biotechnology Investor/Analyst Day to discuss the current treatment landscape and unmet medical need for age related diseases of the eye, and the potential treatment solution UNITY’s lead program, UBX1325 may provide.

Members of UNITY’s senior management team and Key Opinion Leader Robert B. Bhisitkul, MD, Ph.D (University of California San Francisco School of Medicine) will discuss the proposed mechanism of action of UBX1325 and new preclinical data that the supports the senolytic approach in retinal diseases, the most recent UBX1325 clinical data from the BEHOLD study in Diabetic Macular Edema (DME), the ENVISION study in wet Age-related Macular Degeneration (wet AMD), including details of the new 48-week long-term follow-up extension study and near-term value driving milestones.

UBX1325 is an investigational compound being studied for age-related diseases of the eye, including DME and wet AMD that is not approved for any use in any country. UBX1325 is a potent small-molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins.

A Q&A session will follow.